Sidley’s Meena Datta interviewed on the OIG’s anti-kickback request for information
The HHS Proposed rule on safe harbor protection for drug rebates could have the most far-reaching impact on drug prices than any action taken by the Trump Administration to date. In late August the OIG asked for suggestions for potential changes to the Anti-Kickback Statute that could alleviate obstacles to coordinated or value-based care. Partner and Healthcare Practice Leader Meena Datta provides her perspective on these proposals in her recent interview with FierceHealthcare. Read it here.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to United States. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.